PURPOSE: G12C mutations may have distinct clinical characteristics and responses to therapies. EXPERIMENTAL DESIGN: -mutant NSCLC treated at Memorial Sloan Kettering Cancer Center (New York, NY) from 2014 to 2018 and reviewed tumor characteristics, overall survival, and treatment outcomes. CONCLUSIONS: G12C mutations.
No takes yet. Share an insight, caveat, or question.
Arbour et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: